NCDM-32B | CAS#1239468-48-4 | KDM4 inhibitor

MedKoo Cat#: 527665 | Name: NCDM-32B

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NCDM-32B is a novel potent and selective KDM4 inhibitor, impairing viability and transforming phenotypes of basal breast cancer.

Chemical Structure

NCDM-32B

CAS#1239468-48-4

Theoretical Analysis

MedKoo Cat#: 527665

Name: NCDM-32B

CAS#: 1239468-48-4

Chemical Formula: C15H30N2O4

Exact Mass: 302.2206

Molecular Weight: 302.42

Elemental Analysis: C, 59.58; H, 10.00; N, 9.26; O, 21.16

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 405.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NCDM-32B; NCDM32B; NCDM 32B

IUPAC/Chemical Name

Methyl 3-[9-(dimethylamino)nonanoyl-hydroxyamino]propanoate

InChi Key

KDYRPQNFCURCQB-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H30N2O4/c1-16(2)12-9-7-5-4-6-8-10-14(18)17(20)13-11-15(19)21-3/h20H,4-13H2,1-3H3

SMILES Code

O=C(OC)CCN(C(CCCCCCCCN(C)C)=O)O

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T22C03I02

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

NCDM-32B is a potent and selective KDM4 inhibitor that impaires viability and transforming phenotypes of breast cancer.

In vitro activity:

This study investigated the therapeutic potential of a novel histone demethylase inhibitor, NCDM-32B, in breast cancer. The treatment of basal breast cancer cell lines with NCDM-32B resulted in the decrease of cell viability and anchorage independent growth in soft agar. Furthermore, this study found that NCDM-32B impaired several critical pathways that drive cellular proliferation and transformation in breast cancer. Reference: Am J Cancer Res. 2015 Mar 15;5(4):1519-30. https://pubmed.ncbi.nlm.nih.gov/26101715/

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 302.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T, Yang ZQ. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 2015 Mar 15;5(4):1519-30. PMID: 26101715; PMCID: PMC4473328.

In vitro protocol:

In vivo protocol:

TBD

1: Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T, Yang ZQ. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 2015 Mar 15;5(4):1519-30. eCollection 2015. PubMed PMID: 26101715; PubMed Central PMCID: PMC4473328. 2: Inoue S, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono M, Kure S, Ogura T, Matsubara Y, Aoki Y. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Hum Mol Genet. 2014 Dec 15;23(24):6553-66. doi: 10.1093/hmg/ddu376. Epub 2014 Jul 17. PubMed PMID: 25035421.